MET and B-cell chronic lymphocytic leukemia: Notably, many gene sets or pathways were active in both CLL subsets, including high expression levels of MET receptor tyrosine kinase, which prolongs CLL cell survival through STAT3 and AKT phosphorylation (40, 59).